Nuvalent

Nuvalent is creating precisely targeted therapies for patients with cancer designed to overcome the limitations of existing therapies for clinically proven kinase targets. Leveraging deep expertise in structure-based design, Nuvalent develops innovative small molecules with exquisite target selectiv...Read more

Stage

Series B

Employees

11-50

Links

Org chart

Collapse
Christopher Turner
Chief Medical Officer
Deb Miller
Chief Legal Officer
Darlene Noci
Chief Development Officer
Joshua Horan
VP, Chemistry
Henry Pelish
VP, Drug Discovery
John Soglia
VP, Translational Development
Jessie Lin
VP, Corporate Strategy & Portfolio Management
Matthew Metivier
VP, Human Resources
Shannon Dauksis
Senior Director, Program Management
Kristi Byrnes
Director, Quality Assurance